Drug Profile


Latest Information Update: 15 Aug 2002

Price : $50

At a glance

  • Originator Biopharm (UK)
  • Class Antithrombotics; Peptides
  • Mechanism of Action Factor XIII inhibitors; Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 16 Sep 1997 A preclinical study has been added to the pharmacodynamics section
  • 27 Jun 1997 New profile
  • 27 Jun 1997 Preclinical development for Thrombosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top